Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APPLIED VASCULAR ENGINEERING BEGINS CLINICALS FOR CORONARY MICRO STENT; STUDY OF UP TO 700 PATIENTS WILL COMPARE DEVICE TO J&J'S PALMAZ-SCHATZ

This article was originally published in The Gray Sheet

Executive Summary

Patient enrollment for an investigational device exemption study of Applied Vascular Engineering, Inc.'s coronary Micro Stent began the week of Nov. 6. On Nov. 3, AVE received an IDE for the prospective, randomized study, which will compare the Micro Stent to Johnson & Johnson's Palmaz-Schatz device. Patient enrollment is anticipated to continue for six to 12 months, and a premarket approval application for the device could be submitted in 18-24 months, AVE predicts.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005004

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel